Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2016

View Archived Issues

[18F]MK-6240: a PET tracer for the quantification of human neurofibrillary tangles

Vaxart begins phase I trial of oral RSV vaccine

PET using novel [18]F-AmBF3-PSMA derivatives clearly reveals prostate cancer in mice

Shire reports topline clinical results on SHP-465

FDA grants fast track designation to ONT-380

FDA clears Xpert Carba-R Assay

Lipocine receives complete response letter for LPCN-1021

Merck & Co. and Moderna enter collaboration for novel mRNA-based personalized cancer vaccines

Japan Tobacco prepares launch of Genvoya combination tablets in Japan

Galena Biopharma discontinues phase III PRESENT trial after interim analysis

OncBioMune highlights promising progress in cancer vaccine development

Actinium Pharmaceuticals initiates phase III SIERRA study

ACRAF patents DNA gyrase and DNA topoisomerase IV inhibitors

Cara Therapeutics discloses phase II results on CR-845

Bayer Schering Pharma discloses Mnk1 inhibitors

Janssen Pharmaceutica describes PI3Kbeta inhibitors

Roche patent reveals TLR8 agonists

Evotec presents P2X3 receptor antagonists

Cytune Pharma closes financing round

NOVA phase III trial successfully achieves primary endpoint in patients with ovarian cancer

NCI grant supports BioMarker Strategies' development of PathMAP NSCLC companion diagnostic test

Xcovery initiates phase III trial of X-396 in ALK-positive NSCLC

Imbruvica obtains FDA breakthrough therapy designation for new indication

Stempeucel shows efficacy for the treatment of CLI due to Buerger's disease

SER-262 prevents recurrence in patients with primary CDI

European Commission grants orphan drug designation to BPS-804 for osteogenesis imperfecta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...